Proprietary names

Sutures are sold ia the United States under generic and/or proprietary names. The most widely sold sutures are Hsted ia Table 1. The generic names for the synthetic polymeric sutures are those that have been approved by the United States Adopted Names Council (USAN). 

This article discusses the main diseases caused by protozoa and the important chemotherapeutic antiprotozoal agents currently ia use or ia an advanced state of development. Not all alternative proprietary names are given for each dmg. There are excellent sourcebooks on protozoology and parasitology (2—8). 

During the last 160 years, many trivial names have been used for pyrimidine and its derivatives. Some, like uracil, persist but others have now fallen out of use, save for the occasional biochemical or biological paper. Table 1 embraces most such names WHO non-proprietary drug names, trade or proprietary names, and names of some natural products discussed in this chapter are not included because they are readily available elsewhere (B-76MI21303). 

The monomers, eatalysts or hardeners, or plastieizers ean inelude ehemieals with the potential to irritate the skin, mueous membranes or respiratory traet. Some ean promote skin or respiratory sensitization. The range of ehemieals in use is extremely wide, so that referenee should be made to the Materials Safety Data Sheet for eaeh speeifie formulation or variation of it identifiable by referenee to the supplier s proprietary name and eode number. Some eommon resin types are summarized in Table 5.55. 

It has now gained acceptance as an impressed current anode for cathodic protection and has been in use for this purpose since 1971. The anode consists of a thin film of valve and precious metal oxides baked onto a titanium substrate and when first developed was given the proprietary name dimensionally stable anode , sometimes shortened to DSA. Developments on the composition of the oxide film have taken place since Beer s patent, and this type of anode is now marketed under a number of different trade names. 

Patents or trademarks may cover information presented. No authorization to utilize these patents or trademarks is given or implied they are discussed for information purposes only. The use of general descriptive names, proprietary names, trade names, commercial designations, or the like does not in any way imply that they may be used freely. While information presented represents useful information that can be studied or analyzed and is believed to be true and accurate, neither the authors nor the publisher can accept any legal responsibility for any errors, omissions, inaccuracies, or other factors. 

The current official FDA Chlortetracycline Working Standard is chlortetracycline hydrochloride, Lot //501-632B-95-1 (9/29/53), obtained from Lederle, which markets the antibiotic under the proprietary name Aureomycin. The current working standard has an assigned potency of 1000 yg/mg (the term yg applied to chlortetracycline means the chlortetracycline activity (potency) contained in 1 yg of the FDA Chlortetracycline Master Standard (Lot 990-107-141-1), which is also chlortetracycline hydrochloride). 

It should be noted that there are normally three names associated with a drug the trade or proprietary name (e.g., Nexium), generic or nonproprietary name (esomeprazole), and a specific chemical name for the active ingredient. In the case of esomeprazole, the active ingredient is the S-isomer of benzimidazole. 

The proprietary names used in this book can be found in Martindale the Complete Drug Reference, although not all are listed in the British National Formulary. 

---